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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER903The Heart Team of Cardiovascular CareDavid R. Holmes, Jr, Jeffrey B. Rich, William A. Zoghbi, Michael J. Mack
The central goal of patient-centric care requires that the patient and family be sufficiently
educated regarding the available alternatives. Given the wide range of information available
from different cardiovascular specialties and the potential for individual physician biases, team-
based care has great potential merit. Holmes and colleagues illustrate the potential benefits of
the Heart Team approach with examples of percutaneous coronary intervention versus
coronary artery bypass graft and surgical versus percutaneous aortic valve replacement. While
specific strategies for implementation of these teams will vary, this broad approach will
become the standard of cardiovascular care.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY908Aortic Annular Sizing for TAVR Using Cross-Sectional 3D-TEEHasan Jilaihawi, Niraj Doctor, Mohammad Kashif, Tarun Chakravarty, Asim Rafique, Moody Makar,
Azusa Furugen, Mamoo Nakamura, James Mirocha, Mitch Gheorghiu, Jasminka Stegic, Kazuaki Okuyama,
Daniel J. Sullivan, Robert Siegel, James K. Min, Swaminatha V. Gurudevan, Gregory P. Fontana,
Wen Cheng, Gerald Friede, Takahiro Shiota, Raj R. Makkar
Jilaihawi and colleagues compared cross-sectional 3-dimensional (3D) transesophageal
echocardiography (TEE) to 2-dimensional (2D) TEE for predicting aortic regurgitation
after transcatheter aortic valve replacement (TAVR). 2D-TEE measurements had a low
discriminatory value for predicting paravalvular regurgitation. Average cross-sectional diameter
(Dmean) by computed tomography (CT) offered a high degree of discrimination and Dmean
by 3D-TEE was of intermediate value. These results suggest that for patients who cannot
undergo contrast CT imaging, cross-sectional 3D echocardiographic sizing should be
considered.(continued on page A-28)






ECORONARY ARTERY DISEASE917Correlation Between FFR and IVUS Depends on RVDRon Waksman, Jacek Legutko, Jasvindar Singh, Quentin Orlando, Steven Marso, Timothy Schloss,
John Tugaoen, James DeVries, Nicholas Palmer, Michael Haude, Stacy Swymelar, Rebecca Torguson
The FIRST (Fractional Flow Reserve and Intravascular Ultrasound RelationShip Study)
aimed to determine the optimal minimum lumen area (MLA) by intravascular ultrasound
(IVUS) that correlates with fractional flow reserve (FFR) 0.80. A total of 350 patients with
67 intermediate lesions underwent FFR, IVUS, and virtual histology IVUS. The accuracy of
VUS MLA for predicting an FFR 0.8 improved when reference vessel specific analyses
ere performed. MLA of 2.4 mm2 was best for reference vessel diameters (RVDs) of 3.0
mm, MLA 2.7 mm2 for RVD of 3.0 to 3.5 mm, and MLA 3.6 mm2 for RVD 3.5
m. FFR correlated with plaque burden but not with other plaque morphology. Anatomic
easurements by IVUS show a moderate correlation to the FFR values with the optimal cut-
ff for MLA being dependent on the reference vessel diameter.ditorial Comment: Goran Stankovic, Milan Dobric, p. 924CORONARY ARTERY DISEASE926High-Dose Allopurinol Reduces LVM in Patients With Ischemic Heart DiseaseSushma Rekhraj, Stephen J. Gandy, Benjamin R. Szwejkowski, M. Adnan Nadir, Awsan Noman,
J. Graeme Houston, Chim C. Lang, Jacob George, Allan D. Struthers
Rekhraj and colleagues performed a randomized, placebo-controlled trial to determine if
high-dose allopurinol regresses left ventricular mass (LVM) in patients with ischemic heart
disease (IHD). The primary outcome measure was change in LVM, assessed by cardiac
magnetic resonance (CMR). Compared to placebo, allopurinol significantly reduced LVM
and left ventricular mass index (LVMI). Allopurinol also reduced left ventricular end-systolic
volume, improved flow mediated dilation, and lowered the augmentation index. These results
suggest that high-dose allopurinol might reduce future cardiovascular events and mortality in
patients with IHD.
Editorial Comment: Vasileios Karantalis, Hernandez Schulman, Joshua M. Hare, p. 933(continued on page A-30)
MARCH 5, 2013 (continued) A-30PCARDIAC RESYNCHRONIZATION936Influence of LVEF on the Effectiveness of CRTValentina Kutyifa, Axel Kloppe, Wojciech Zareba, Scott D. Solomon, Scott McNitt, Slava Polonsky,
Alon Barsheshet, Bela Merkely, Bernd Lemke, Vivien Klaudia Nagy, Arthur J. Moss, Ilan Goldenberg
Kutyifa and colleagues reviewed the baseline echocardiograms from patients enrolled in the
MADIT-CRT trial, which randomized patients to cardiac resynchronization therapy with
defibrillator (CRT-D) or implantable cardioverter-defibrillator (ICD). The percentage
decrease in left ventricular end-diastolic volume at 1 year was greater in those with higher
baseline left ventricular ejection fraction (LVEF). CRT-D treatment reduced the risk of heart
failure/death to a similar degree regardless of baseline LVEF. These results show that the
clinical benefit of CRT may extend to those with LVEF30%.Editorial Comment: Maurizio Gasparini, Paola Galimberti, p. 945HEART FAILURE
948rophylactic Steroid Therapy Improves All-Cause
Mortality and Cardiovascular Outcomes in Patients With DMDGernot Schram, Anne Fournier, Hugues Leduc, Nagib Dahdah, Johanne Therien, Michel Vanasse,
Paul Khairy
Duchenne muscular dystrophy (DMD) results in progressive musculoskeletal weakness caused
by a lack of functional dystrophin, with death often caused by cardiomyopathy. Therapeutic
studies suggest that antagonists of the renin angiotensin-aldosterone system delay the
progression of left ventricular dysfunction, and that steroid treatment prolongs the period of
ambulation and improves forced vital capacity. Schram and colleagues conducted a cohort
study on patients with DMD treated with renin-angiotensin-aldosterone system antagonists
with or without steroid therapy and show that steroid therapy is associated with improved
survival driven by fewer heart failure-related deaths (0% vs. 22%), a lower rate of new-onset
cardiomyopathy, and slower rates of decline in left ventricular ejection fraction. In patients
with DMD, steroid therapy is associated with a substantial reduction in all-cause mortality
and new-onset and progressive cardiomyopathy.
Editorial Comment: G. William Dec, p. 955(continued on page A-32)
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957eta-Analysis Confirms Link Between the Chromosome 9p21 Locus
and the Severity of CADKenneth Chan, Riyaz S. Patel, Paul Newcombe, Christopher P. Nelson, Atif Qasim, Stephen E. Epstein,
Susan Burnett, Viola L. Vaccarino, A. Maziar Zafari, Svati H. Shah, Jeffrey L. Anderson, John F. Carlquist,
Jaana Hartiala, Hooman Allayee, Kunihiko Hinohara, Bok-Soo Lee, Anna Erl, Katrina L. Ellis, Anuj Goel,
Arne S. Schaefer, Nour Eddine El Mokhtari, Benjamin A. Goldstein, Mark A. Hlatky, Alan S. Go,
Gong-Qing Shen, Yan Gong, Carl Pepine, Ross C. Laxton, John C. Whittaker, W.H. Wilson Tang,
Julie A. Johnson, Qing K. Wang, Themistocles L. Assimes, Ute Nöthlings, Martin Farrall, Hugh Watkins,
A. Mark Richards, Vicky A. Cameron, Axel Muendlein, Heinz Drexel, Werner Koch, Jeong Euy Park,
Akinori Kimura, Wei-feng Shen, Iain A. Simpson, Stanley L. Hazen, Benjamin D. Horne,
Elizabeth R. Hauser, Arshed A. Quyyumi, Muredach P. Reilly, Nilesh J. Samani, Shu Ye
Chromosome 9p21 variants have been robustly associated with coronary heart disease, but
whether the locus contributes to coronary atheroma burden or plaque instability is unclear.
Chan and colleagues performed a meta-analysis of 21 studies. The results confirmed an
association between 9p21 and coronary artery disease (CAD) using angiographically defined
cases and controls. Among subjects with angiographic CAD, the odds ratio for multivessel
CAD compared to single-vessel disease, was 1.10 per copy of risk allele. There was no
significant association between 9p21 and prevalent MI when both cases and controls had
underlying CAD. These results add further weight to the hypothesis that the 9p21 locus
primarily mediates an atherosclerotic phenotype.PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH
971etformin Impairs Vascular Endothelial Recovery Particularly in
Combination With mTOR Inhibitors Such as Sirolimus, Zotarolimus, or EverolimusAnwer Habib, Vinit Karmali, Rohini Polavarapu, Hirokuni Akahori, Masataka Nakano, Saami Yazdani,
Fumiyuki Otsuka, Kim Pachura, Talina Davis, Jagat Narula, Frank D. Kolodgie, Renu Virmani,
Aloke V. Finn
Some evidence suggests that both metformin and mammalian target of rapamycin (mTOR)
inhibitors, such as sirolimus, zotarolimus or everolimus, delay endothelial recovery. Habib and
colleagues examined points of molecular convergence between these 2 agents in cultured
endothelial cells. Human aortic endothelial cell proliferation was significantly inhibited by
metformin or sirolimus exposure alone, and further reduced when they were combined.
Endothelialization and endothelial cell proliferation in rabbits receiving zotarolimus-eluting
stents (ZES) or bare-metal stents were inhibited by ZES treatment alone and further by the
combination of metformin and ZES. This study indicates that metformin interacts with
mTOR signaling and further suppress endothelial proliferation after treatment with drug-
eluting stents.
